| Product Code: ETC10416484 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Romania Relapsing Remitting Multiple Sclerosis Market Overview |
3.1 Romania Country Macro Economic Indicators |
3.2 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, 2021 & 2031F |
3.3 Romania Relapsing Remitting Multiple Sclerosis Market - Industry Life Cycle |
3.4 Romania Relapsing Remitting Multiple Sclerosis Market - Porter's Five Forces |
3.5 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume Share, By Mechanism of Action, 2021 & 2031F |
3.7 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Romania Relapsing Remitting Multiple Sclerosis Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of relapsing-remitting multiple sclerosis (RRMS) in Romania |
4.2.2 Growing awareness and diagnosis rates of RRMS in the country |
4.2.3 Advancements in RRMS treatment options and therapies |
4.2.4 Supportive government initiatives for improving access to RRMS treatments |
4.3 Market Restraints |
4.3.1 High cost of RRMS medications and treatments |
4.3.2 Limited healthcare infrastructure and resources for managing RRMS patients |
4.3.3 Regulatory challenges and delays in the approval of new RRMS therapies |
4.3.4 Lack of specialized healthcare professionals with expertise in treating RRMS |
5 Romania Relapsing Remitting Multiple Sclerosis Market Trends |
6 Romania Relapsing Remitting Multiple Sclerosis Market, By Types |
6.1 Romania Relapsing Remitting Multiple Sclerosis Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Drug Type, 2021 - 2031F |
6.1.3 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Immunomodulators, 2021 - 2031F |
6.1.4 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Monoclonal Antibodies, 2021 - 2031F |
6.1.5 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Interferons, 2021 - 2031F |
6.1.6 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By S1P Receptor Modulators, 2021 - 2031F |
6.2 Romania Relapsing Remitting Multiple Sclerosis Market, By Mechanism of Action |
6.2.1 Overview and Analysis |
6.2.2 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By T-Cell Suppression, 2021 - 2031F |
6.2.3 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By B-Cell Targeting, 2021 - 2031F |
6.2.4 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Cytokine Regulation, 2021 - 2031F |
6.2.5 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Immune Cell Migration, 2021 - 2031F |
6.3 Romania Relapsing Remitting Multiple Sclerosis Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Oral, Injectable, 2021 - 2031F |
6.3.3 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By IV Infusion, 2021 - 2031F |
6.3.4 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Subcutaneous, Intramuscular, 2021 - 2031F |
6.3.5 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Oral, 2021 - 2031F |
6.4 Romania Relapsing Remitting Multiple Sclerosis Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Hospitals, Clinics, 2021 - 2031F |
6.4.3 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Specialty Centers, 2021 - 2031F |
6.4.4 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Homecare, Clinics, 2021 - 2031F |
6.4.5 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Neurology Centers, 2021 - 2031F |
6.5.2 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Distribution Channel, 2021 - 2031F |
6.5.3 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Retail Pharmacies, Online Pharmacies, 2021 - 2031F |
6.5.4 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Specialty Pharmacies, Hospital Pharmacies, 2021 - 2031F |
6.5.5 Romania Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Online Drug Stores, 2021 - 2031F |
7 Romania Relapsing Remitting Multiple Sclerosis Market Import-Export Trade Statistics |
7.1 Romania Relapsing Remitting Multiple Sclerosis Market Export to Major Countries |
7.2 Romania Relapsing Remitting Multiple Sclerosis Market Imports from Major Countries |
8 Romania Relapsing Remitting Multiple Sclerosis Market Key Performance Indicators |
8.1 Patient adherence rate to RRMS treatment plans |
8.2 Average time to diagnosis of RRMS patients |
8.3 Number of RRMS clinical trials conducted in Romania |
8.4 Percentage of RRMS patients accessing specialized care and support services |
8.5 Rate of utilization of RRMS disease-modifying therapies |
9 Romania Relapsing Remitting Multiple Sclerosis Market - Opportunity Assessment |
9.1 Romania Relapsing Remitting Multiple Sclerosis Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 Romania Relapsing Remitting Multiple Sclerosis Market Opportunity Assessment, By Mechanism of Action, 2021 & 2031F |
9.3 Romania Relapsing Remitting Multiple Sclerosis Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Romania Relapsing Remitting Multiple Sclerosis Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Romania Relapsing Remitting Multiple Sclerosis Market - Competitive Landscape |
10.1 Romania Relapsing Remitting Multiple Sclerosis Market Revenue Share, By Companies, 2024 |
10.2 Romania Relapsing Remitting Multiple Sclerosis Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here